A 56-year-old client with suspected leukemia is scheduled for a bone marrow biopsy this morning. During the pre-procedure assessment, the nurse reviews the client's laboratory results and current medications. Which assessment finding would be most important for the nurse to report to the healthcare provider before the procedure?

Pre-procedure Assessment for Bone Marrow Biopsy

A bone marrow biopsy is an invasive procedure that involves puncturing the bone (typically the posterior iliac crest) to obtain a core of bone marrow tissue. Because the bone is highly vascular, the most significant procedural risk is bleeding. When reviewing a client's pre-procedure laboratory values, the nurse must identify which abnormal finding poses the greatest immediate threat to safety.

Analysis of Assessment Findings

The correct answer is the platelet count of 45,000/mm³. This value represents severe thrombocytopenia. Platelets are essential for primary hemostasis, forming the initial plug at the site of vascular injury. A count below 50,000/mm³ is associated with an increased risk of bleeding during invasive procedures ^[1]. The clinical implications of hematological abnormalities, such as thrombocytopenia, are critical considerations for the safety of invasive procedures, as the body's ability to achieve hemostasis is directly compromised ^[1]. While the liver's synthesis of coagulation factors is often a concern, a low platelet count represents an immediate, quantitative deficit in the cellular component of clot formation that cannot be overcome by a normal coagulation cascade alone.

The other options, while representing abnormal findings, are less critical to report immediately before the procedure:

• Hemoglobin of 8.5 g/dL: This indicates moderate anemia, which is common in leukemia due to bone marrow crowding. While it requires monitoring and eventual treatment, it does not pose an immediate procedural risk of hemorrhage.


• White blood cell count of 2,500/mm³: This indicates leukopenia, which raises the risk of infection. However, the immediate risk of bleeding from the biopsy takes priority over the longer-term infection risk in the pre-procedure time-out.


• INR of 1.2: This value is within the normal therapeutic range (typically 0.8–1.2). It indicates a normal extrinsic coagulation pathway and would not be a cause for concern or a reason to delay the procedure.

Clinical Reasoning and Pathophysiology

The pathophysiology of leukemia involves the overproduction of abnormal white blood cells in the bone marrow, which crowds out the normal hematopoietic stem cells. This leads to a suppression of normal cell lines, including the megakaryocytes that produce platelets. The resulting thrombocytopenia means the patient lacks the initial cellular response to endothelial injury. During a bone marrow biopsy, the needle disrupts the bone's vascular sinusoids. Without an adequate number of circulating platelets, the formation of a stable platelet plug is impaired, significantly increasing the risk of persistent oozing or serious hemorrhage at the biopsy site. This directly connects the pathophysiological mechanism of the disease to the clinical risk of the procedure. The prevalence of such abnormalities is well-documented, with studies showing thrombocytopenia is a very common finding in conditions affecting the marrow and liver, carrying significant implications for procedural planning ^[1].